摘要
目的探讨氟尿嘧啶联合亚叶酸钙（5-FU／CF）与奥沙利铂联合5-FU／CF（FOLFOX4）两种辅助化疗方案用于Ⅱ～Ⅲ期大肠癌根治术后患者临床疗效和安全性差异。方法选取临汾市肿瘤医院2010年7月至2013年7月收治的Ⅱ-Ⅲ期大肠癌根治术后患者共110例为研究对象，以随机区组法分为A组（55例）和B组（55例），分别采用5-FU／CF方案和FOLFOX4方案辅助化疗；比较两组患者复发转移率、生存时间及药物毒副作用发生率。结果B组复发和转移率分别为18．18％和25．45％，显著低于A组（34．55％、63．64％），差异均有统计学意义（χ^2=9．12、8．74，均P〈0．05）；B组患者中位生存时间（31．4个月）显著长于A组（20．7个月），差异有统计学意义（HR=1．83，95％CI：1．16D．74，均P〈0.05）；A组患者恶心呕吐、食欲不振、脱发及贫血发生率分别为83．64％、61．82％、60．00％、18．18％，B组患者恶心呕吐、食欲不振、脱发及贫血发生率分别为89．09％、69．09％、63．64％、23．64％，两组患者药物毒副作用发生率差异均无统计学意义（χ^2=1．72、2．54、1．04、2．47，均P〉0．05）。结论相较于5-FU／CF方案，FOLFOX4方案辅助用于Ⅱ～Ⅲ期大肠癌根治术后患者可有效降低转移复发风险，延长生存时间，且未增加药物毒副作用发生风险及程度。
Objective To compare the clinical effects and safety of two kinds of adjuvant chemotherapy in treatment of patients with colon cancer with Ⅱ～Ⅲ stage after radical resection including 5 - FU/CF scheme and FOLFOX4 scheme. Methods 110 patients with colon cancer with Ⅱ～Ⅲ stage after radical resection were chosen from July 2010 to July 2013 in our hospital and were randomly divided into two groups.,A group （55 patients） was given 5 -FU/CF scheme and B group （55 patients） received FOLFOX4 scheme. The recurrence and metastasis rate with follow-up, survival time and drug side effects incidence were compared between the two groups. Results The recurrenoe and metastasis rates With follow-up of B group（ 18.18% ,25.45% ） were significantly better than A group （34.55% ,63.64% ） （χ^2= 9.12,8.74, all P 〈 0.05 ）. The median survival time of B group （31.4 months） was sig- nitlcantly longer than A group （20.7months） （ HR = 1.83,95 % CI： 1.16 - 3.74, all P 〈 O. 05 ）. The incidence rates of nausea and vomiting,loss of appetite,hair loss and anemia of A group were 83.64% ,61.82% ,60.00%, 18.18% ; which of B group were 89.09% ,69.09% ,63.64% ,23.64% ;there were no significant differences in incidence rates of drug side effects between the two groups （χ^2= 1.72,2.54,1.04,2.47, all P 〉 0.05 ）. Conclusion Compared with 5 - FU/CF scheme, FOLFOX4 scheme in treatment of patients with colon cancer with II - Ill stage after radical resection can efficiently reduce the risk of recurrence and metastasis, prolong the survival time and not increase the risk and extent of drug adverse effects.
出处
《中国基层医药》
CAS
2016年第6期867-869,共3页
Chinese Journal of Primary Medicine and Pharmacy
关键词
大肠肿瘤
抗肿瘤联合化疗方案/治疗应用
Colorectal neoplasms
Antineoplastic combined chemotherapy protocols/therapeutic application
